New combo aims to stop bleeding in bone marrow disease
NCT ID NCT07653581
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether adding a platelet-boosting drug (rhTPO) to standard cyclosporine therapy can safely raise platelet counts in 78 adults with lower-risk myelodysplastic syndromes (MDS) who have very low platelets. The goal is to reduce bleeding and the need for platelet transfusions. Participants will be randomly assigned to receive either the combination or cyclosporine alone.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- recombinant human thrombopoietin (rhTPO) and cyclosporine (CsA)
- What this could lead to
- If it works, this could offer a new way to raise platelet counts and reduce bleeding in people with lower-risk MDS.
- What could go wrong
- This is a small, single-center trial that hasn't started yet. The combination may not work better than cyclosporine alone, and both drugs have side effects like infection risk or kidney issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 78 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age ≥ 18 years old; 2. Confirmed diagnosis of lower-risk MDS; 3. Platelet ≤ 30×109/L, or \< 50×109/L and accompanied by bleeding events; 4. Baseline liver and kidney functions \<2 ULN; 5. Signed the informed consent form; 6. ECOG 0-2; Exclusion Criteria: 1. History of leukemia or stem cell transplantation, treatment-related MDS or malignant tumors; 2. With splenomegaly or myelofibrosis; 3. Infections or bleeding that cannot be controlled by standard treatment; 4. Any concurrent malignant tumors within the past 5 years, or basal cell carcinoma of the skin at the local site; 5. History of thromboembolic events, heart attack or stroke and current use of anticoagulants; 6. Previously received cyclosporine (CsA) or ATG within 6 months; 7. Previously used IL-11, rhTPO or TPO-RA; 8. Pregnant or lactating women; 9. Participated in other clinical trials within 3 months.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lower-risk myelodysplastic syndromes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.